ALEMBIC PHARMACEUTICALS LTD. Q4 FY26 Results

Summary

Alembic Pharmaceuticals Limited reported a mixed financial performance for the fourth quarter and full financial year ended March 31, 2026. Revenue from operations for Q4 FY26 increased by 9.43% year-on-year to ₹1,718.74 crore, contributing to a full-year revenue growth of 10.26% to ₹6,651.38 crore. However, the company's profit for the period (PAT) saw a significant decline, falling by 34.52% in Q4 FY26 to ₹105.37 crore and by 15.70% for the full year to ₹462.67 crore. This profit contraction was notably impacted by exceptional items, including an ₹18.35 crore write-down related to the Sikkim manufacturing facility classified as held for sale and an accounting impact from new Labour Codes. The company's board also recommended a dividend.

Key Highlights

1. 1

   Alembic Pharmaceuticals reported Q4 FY26 revenue from operations at ₹1,718.74 crore, marking a 9.43% year-on-year increase compared to Q4 FY25.

2. 2

   For the full financial year FY26, revenue from operations grew by 10.26% to ₹6,651.38 crore compared to FY25.

3. 3

   Profit for the period (PAT) for Q4 FY26 stood at ₹105.37 crore, reflecting a 34.52% decrease from ₹160.91 crore reported in Q4 FY25.

4. 4

   Full-year FY26 profit for the period (PAT) declined by 15.70% to ₹462.67 crore against ₹548.83 crore in FY25.

5. 5

   EBITDA for Q4 FY26 was ₹299.94 crore, resulting in an EBITDA margin of 17.45%.

6. 6

   The company recorded exceptional items totaling ₹24.76 crore in Q4 FY26, primarily due to an incremental impact from revised Labour Codes and a write-down of ₹18.35 crore for the Sikkim manufacturing facility.

7. 7

   The Board of Directors has recommended a dividend for the financial year ended 31st March, 2026.